CLINICAL RESEARCH IN NEURO-ONCOLOGY

罗伊·A·帕切尔博士的整个医疗生涯一直致力于以患者为中心的临床神经肿瘤学研究。他在约翰·霍普金斯大学完成了神经学住院医师学位，并在纪念斯隆-凯特琳癌症中心获得了临床神经肿瘤学研究员学位。然后他来到肯塔基大学，制定了一个全面的临床神经肿瘤学研究计划。这涉及到许多临床试验的发展，研究转移性和原发性脑肿瘤的治疗。在所有这些研究中，帕切尔博士一直是首席研究员。自1986年以来，他一直获得持续的外部资金，自1988年以来，他一直获得NIH的RO1资金，目前他获得了RO1资金。他所有的RO1资金都用于临床神经肿瘤学试验。除了过去和目前正在进行的评估神经系统癌症常用治疗方法的疗效的临床试验外，帕切尔博士还发明了一种植入式、可再填充的缓释装置，用于治疗原发脑肿瘤的肿瘤内化疗。该设备目前正在由Patchell博士设计的几个I期和II期试验中使用，其中一项研究已成为放射治疗肿瘤学小组(RTOG)主持下的全国性试验。帕切尔博士正在继续与肯塔基大学的基础科学家合作，研究该设备的进一步用途，包括与非常规药物的使用，如抗血管生成因子、生物反应调节剂、辐射细胞增敏剂和其他化合物。帕切尔博士有积极指导肯塔基大学实习医生、研究员和初级教员等临床研究新秀的良好记录。1995年，他建立了神经肿瘤学研究员培训计划，目前正在培训神经肿瘤学研究员。Patchell博士的职业目标包括获得额外的外部资金，以便他能够扩大神经肿瘤研究员培训计划，并继续将他的大部分时间投入到指导他的神经肿瘤研究员以及开发原发和转移性脑瘤的新疗法上。

Dr. Roy A. Patchell's entire medical career has been devoted to patient oriented clinical Neuro-Oncology research. He completed a residency in Neurology at Johns Hopkins and a fellowship in clinical Neuro Oncology at Memorial Sloan-Kettering Cancer Center. He then came to the University of Kentucky and ha developed a comprehensive clinical Neuro-Oncology research program. This has involved the development of numerous clinical trials investigating the treatment of metastatic and primary brain tumors. On all of these studies, Dr. Patchell has been the principal investigator. He has had continuous extramural funding since 1986 and continuous RO1 NIH funding since 1988 and has a currently funded RO1 grant. All of his RO1 funding has been for clinical Neuro-Oncology trials. In addition to past and currently ongoing clinical trials assessing the effects of commonly available therapies for cancers of the nervous system, Dr. Patchell has invented an implantable, refillable, sustained-release device for the delivery of intratumoral chemotherapy for primary brain tumors. This device is currently being used in several phase I and phase II trials designed by Dr. Patchell, and one study has become a national trial under the auspices of the Radiation Therapy Oncology Group (RTOG). Dr. Patchell is continuing to collaborate with basic scientists at the University of Kentucky to investigate further uses of the device, including use with non-conventional agents such as anti-angiogenesis factors, biological response modifiers, radiation cell sensitizers, and other compounds. Dr. Patchell has a strong record of actively mentoring budding clinical investigators including residents, fellows, and junior faculty members at the University of Kentucky. In 1995, he established a Neuro-Oncology Fellowship Training Program and is currently training Neuro-Oncology Fellows. Dr. Patchell's careers goals include obtaining additional external funding so that he can expand the Neuro-Oncology Fellowship training program and continue to devote the majority of his time to mentoring his Neuro-Oncology Fellows and to developing new treatments for primary and metastatic brain tumors.